Electrochemiluminescence immunoassay “ECLIA” for the in vitro quantitative determination of PCT (procalcitonin) in human serum and plasma
The Elecsys® BRAHMS PCT assay can be used to aid in the early detection of clinically relevant bacterial infections. Increased PCT levels are often found in patients suffering from bacterial sepsis, especially severe sepsis and septic shock, and was found to be a reliable indicator of severity and of major complications in acute pancreatitis.
In patients suffering from community-acquired respiratory tract infections or ventilator‑induced pneumonia PCT has been proposed as a guide for the decision of antibiotic treatment necessity and to monitor treatment success.
ECL (ElectroChemiLuminescence) is Roche’s technology for immunoassay detection. Based on this technology and combined with well-designed, specific and sensitive immunoassays, Elecsys® delivers reliable results. The development of ECL immunoassay is based on the use of a ruthenium-complex and tripropylamine (TPA).
The chemiluminescence reaction for the detection of the reaction complex is initiated by applying a voltage to the sample solution, resulting in a precisely controlled reaction. ECL technology can accommodate many immunoassay principles while providing excellent performance.
* LoB = Limit of Blank; LoD = Limit of Detection; LoQ = Limit of Quantitaion (the lowest analyte concentration that can be reproducibly measured with an intermediate precision CV of ≤ 20 %).
** only for values > 0.1 ng/mL
*** Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges
Source: Procalcitonin Method Sheet document 09318747500V1.0 and 09318712500V.2.0